Table 2.
Primers used in this study
Purpose, primer | Sequencea |
---|---|
qRT-PCR | |
ACT1-F | 5′-ACGGTGAAGAAGTTGCTGCTTTAGTT-3′ |
ACT1-R | 5′-CGTCGTCACCGGCAAAA-3′ |
18S-F | 5′-CACGACGGAGTTTCACAAGA-3′ |
18S-R | 5′-CGATGGAAGTTTGAGGCAAT-3′ |
ERG11-F | 5′-CCCCTATTAATTTTGTTTTCCCTAATTTAC-3′ |
ERG11-R | 5′-CACGTTCTCTTCTCAGTTTAATTTCTTTC-3′ |
CDR1-F | 5′-ATTCTAAGATGTCGTCGCAAGATG-3′ |
CDR1-R | 5′-AGTTCTGGCTAAATTCGTAATGTTTTC-3′ |
CDR2-F | 5′-TAGTCCATTCAACGGCAACAAT-3′ |
CDR2-R | 5′-CACCCAGTATTTGGCATTGAAA-3′ |
BMR1-F | 5′-ACATAAATACTTTGCCCATCCAGAA-3′ |
BMR1-R | 5′-AAGAGTTGGTTTGTAATCGGCTAAA-3′ |
UPC2 mutant construction | |
UPC2-A | 5′-GGGCCCGAGATCTTGATGTCATTAG-3′ |
UPC2-B | 5′-CTCGAGCTATATCTTCAATGAACTG-3′ |
UPC2-E | 5′-CTCGAGCACCACAGTAACGAATCAC-3′ |
UPC2-C | 5′-CCGCGGACAGGTCAATACCGCGTAG-3′ |
UPC2-D | 5′-GAGCTCGTTCCTCTAGTATCACTCTT-3′ |
UPC2 sequencing | |
UPC2seqA | 5′-CTGCAGAGAATCACAGTGAAGTTC-3′ |
UPC2seqB | 5′-CTCAGCCGGTGATTCCTCCA-3′ |
UPC2seqC | 5′-CGGTCAAACCTCAATATGCTTGAC-3′ |
UPC2seqD | 5′-GTTTCCAGTGCTTTTGGACTCTCC-3′ |
UPC2seqZ | 5′-CCTATCATCTACGCGGTATTGACC-3′ |
UPC2seqF | 5′-TGGAGGAATCACCGGCTGAG-3′ |
UPC2seqG | 5′-GTCAAGCATATTGAGATTTGACCG-3′ |
UPC2seqH | 5′-GGAGAGTCCAAAAGCACTGGAAAC-3′ |
Underlined sequence reflects the introduction of a restriction site sequence.